US · Healthcare · Biotechnology
EPS came in at -1.78 against a street estimate of -1.48 — a miss of 20.3%.
Analysts rate Nektar Therapeutics a buy (4 buy, 3 hold, 1 sell out of 8) with an average price target of $153.22.
| Fund | Stake |
|---|---|
| FMR Inc | 12.74% |
| Bvf Inc | 7.58% |
| Two Seas Capital LP | 5.80% |
| Vanguard Capital Management, LLC | 3.54% |
| Two Sigma Investments LLC | 2.75% |
| Prosight Management, LP | 2.18% |
| BlackRock Inc | 2.05% |
| Morgan Stanley - Brokerage Accounts | 1.95% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-05 |
| Material agreement · Q2 2026 | 2026-05-08 |
| Quarterly report · Q1 2026 | 2026-05-08 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-24 |
| Material agreement · Q2 2026 | 2026-04-23 |
| Annual report FY2025 | 2026-03-13 |
| Quarterly report · Q3 2025 | 2025-11-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Nektar Therapeutics — free to start.
Google PlayApp StoreData updated 2026-08-05.